Examining the uptake, retention, and effectiveness of a national online type 2 diabetes self-management intervention in England (Healthy Living): A retrospective cohort study Authors: Salwa S. Zghebi, Sarah Cotterill, Antonia Marsden, Luke Paterson, Rachel A. Elliott, Brian McMillan, Martin K. Rutter, Evangelos Kontopantelis, Marcelo Nakazone, Marcelo Nakazone, Marcelo Nakazone Published: 2026 ABSTRACT BackgroundThe prevalence of type 2 diabetes (T2DM) is increasing rapidly in the UK and worldwide and is linked to adverse outcomes including premature death. Previous studies have shown that developing self-management skills in this population can lead to health improvements. The National Health Service in England has implemented Healthy Living (HL), an online Diabetes Self-Management Education and Support (DSMES) intervention, offering information about T2DM and help with adopting healthy behaviours.AimsTo examine the uptake and retention of people living with T2DM registered with Healthy Living and how its use is associated with changes in 1-year clinical outcomes (effectiveness) compared with people with T2DM who did not register (controls).MethodsAnonymised linked patient-level Healthy Living and National Diabetes Audit (NDA) data were used to identify adults with T2DM in England. Multivariable logistic regression models identified predictors of participation in Healthy Living (uptake). Using 1-to-5 case-control propensity score matching (on age, sex, baseline HbA1c, body mass index (BMI), blood pressure (BP), cholesterol, ethnicity, deprivation) and multivariable linear and logistic models, we examined how Healthy Living use was related to 1-year HbA1c, BMI, BP, new insulin use, and completion of eight care processes recommended for people with diabetes (effectiveness). Several sensitivity and sub-group analyses were conducted to assess the robustness of the findings.ResultsA total of 21,820 people with T2DM activated a Healthy Living account. Compared with non-participants, account activators (cases) were more likely to be female (OR: 1.91; 95%CI: 1.85, 1.96), less likely to be Asian (OR: 0.35; 95% CI: 0.33, 0.37) or Black (OR: 0.56; 95% CI: 0.52, 0.60) compared with white people. Assessing effectiveness, 4,940 Healthy Living cases were matched to 24,685 NDA controls. Compared with controls, at 1-year, Healthy Living cases had lower HbA1c (by −1.3 mmol/mol (95% CI: −1.7, −0.8) or −0.1% (95% CI: −0.2, −0.1)); BMI (−0.2 kg/m2; 95% CI: −0.3, −0.1), systolic BP (−1.2 mmHg; 95% CI: −1.6, −0.7), and diastolic BP (−0.6 mmHg; 95% CI: −0.9, −0.3); higher odds of completing care processes (OR: 1.6; 95% CI: 1.5, 1.8), but non-significant for insulin use (OR: 1.0; 95% CI: 0.8, 1.2). The results of the sensitivity and sub-group analyses were consistent with the main findings.ConclusionsPeople who activated a Healthy Living account experienced, on average, moderate health benefits compared with non-participants. These benefits would be expected to reduce risks for diabetes-related complications at a population level. 1. Introduction Diabetes mellitus is one of the most common long-term noncommunicable conditions worldwide [1]. The prevalence of diabetes has increased rapidly over recent decades [2,3]. It is currently estimated that 537 million adults have diabetes, projected to increase to 643 million by 2030 and 783 million by 2045. [2] In the United Kingdom (UK), diabetes prevalence has doubled in the last 15 years and it has been described as the fastest growing health threat [4,5], currently affecting >5.8 million people, of which nearly 4.6 million people live with diabetes diagnoses [6]. Direct diabetes care costs in the UK were £10.7 billion for 2021/22, accounting for 6.3% of the total National Health Service (NHS) budget in 2023/24, with projections to increase to £17.9 billion over 15 years [7]. Type 2 diabetes (T2DM) is the most common form, affecting 90–95% of all people with diabetes with a prevalence of 7% [8,9]. T2DM is associated with microvascular and macrovascular complications including blindness, amputations, and cardiovascular disease (CVD), and increased risk of premature death compared with people without diabetes [10,11]. Previous studies have shown improvements in health outcomes in people with diabetes who are equipped with self-management skills or engaged in education programmes [12–15]. Several structured diabetes self-management education and support (DSMES) programmes exist, which provide guidance on making changes, e.g., improving diet and physical activity, medication adherence, and learning to cope with negative emotions [16]. For example, the Diabetes Education and Self-Management for Ongoing and Newly Diagnosed (DESMOND), that is recommended by the UK’s National Institute for Health and Care Excellence (NICE) [17–19], reported improvements in 1-year body weight loss outcome, but no evidence of a difference to glycated haemoglobin (HbA1c) levels [19]. Some systematic reviews reported the effectiveness of digital DSMES in improving HbA1c in people with T2DM by −0.6% at 12 months [20,21]. Digital interventions offer a suitable alternative by overcoming barriers often faced by participants of in-person sessions, for example, work, caring responsibilities, costs, or comorbidities [22]. It is recommended that effective management of long-term conditions should also consider reducing health inequalities, as interventions that are more effective in advantaged populations may increase disparity [23]. HeLP-Diabetes was shown to be a cost-effective web-based digital DSMES programme for people with T2DM where trial participants achieved lower 1-year HbA1c levels compared with usual care (control group) (−0.24%; 95% CI: −0.44, -0.049) [24–26]. In 2019, NHS England commissioned the development and national rollout of HeLP-Diabetes, named Healthy Living for People with type 2 diabetes (Healthy Living). Unlike HeLP-Diabetes, which was an unstructured programme with facilitated access via general practice and included a moderated discussion forum, Healthy Living is a self-contained and self-directed online programme. The Healthy Living website is composed of 895 web pages containing videos, articles, tools, and self-assessment quizzes [27]. The content is broadly divided into three main sections: 1) the ‘Learn journey’ section: a structured curriculum comprised of different educational modules, 2) the ‘Find answers’ section: unstructured content section dedicated to different type 2 diabetes-related topics, and 3) the ‘Tools’ section: includes a range of Goals and Tracker tools based on the HeLP-Diabetes website where service users can set goals and self-monitor their health. More information on the intervention and its development timeline has been reported previously from this programme of work [27,28]. Given that the NHS is investing in implementing Healthy Living across England after the HbA1c reduction observed in HeLP-Diabetes, it was important to examine whether the national-level roll-out of Healthy Living shows similar benefits. In this study, we aimed to examine if there was variation in uptake and retention of participants with T2DM in the Healthy Living programme in England, by age, sex, and other characteristics. We also examined the programme’s effectiveness across several clinical outcomes at 1-year, compared with people with T2DM who did not take part in the programme. 2. Methods 2.1. Data sources Patient-level data from three linked datasets were used in the analyses: ‘Healthy Living user details’ dataset, ‘Healthy Living engagement’ dataset, and the ‘National Diabetes Audit (NDA)’. The datasets were linked using pseudonymised NHS number or the Healthy Living user identifier. The ‘Healthy Living user details’ dataset included data on the baseline demographics of people with T2DM registered with Healthy Living up to September 2023 in the evaluation period. The ‘Healthy Living engagement’ dataset included data on the engagement and usage activities of participants with Healthy Living educational modules and content. The NDA, which covers most of the English population with T2DM [29], provided data on the audit years 2020−2021, 2021−2022 and 2022−2023, including demographics (age, sex, ethnicity, social deprivation level), diabetes diagnosis date, clinical data (HbA1c, cholesterol, blood pressure, comorbidities), body mass index (BMI), and medications. Each audit year spanned 15 months between January and March the following year. To account for duplicate entries of measures recorded during the annually overlapping January to March period between each two consecutive audit years, we deduplicated these measures by using only one measure per participant per calendar year (e.g., an HbA1c measure dated February 2021 would appear twice, in years 2020−21 and 2021−22). 2.2. Study population People with T2DM aged ≥18 years in England from the Healthy Living user dataset and the NDA were eligible for inclusion in the study cohort. Participants with missing pseudonymised NHS number were excluded (9% of the total cohort). Based on definitions described in Table 1, the study population was categorised into five study groups: Not registered with Healthy Living (Group 1); Registered with Healthy Living (Group 2); Activated a Healthy Living account (Group 3); Attended Healthy Living (Group 4); and Completed Healthy Living programme (Group 5). 10.1371/journal.pone.0348266.t001Table 1Definitions used to define the study population groups.• Registered with Healthy Living (HL) (Group 2): To gain access to the HL website, participants registered online giving their type 2 diabetes status, name, email address, gender, date of birth, postcode, and how they heard about HL.• Activated HL account (Activators) (Group 3): Following registration, participants were sent an email with a link to complete their profile and activate their account. Participants were then able to access the intervention or programme content.• Attended/attendance (Group 4): if an engagement (completed activation and completed the first module of the Learn Journey, “Introduction to type 2 diabetes”) is recorded for a user within 9 months (274 days, inclusive) of account creation date.• Completed/completion (Group 5): if a user accessed the 60% trigger point within the Learn Journey within 9 months (274 days, inclusive) of account creation date.• Uptake: the extent to which people with T2DM start Healthy Living (HL), defined as account creation.• Retention: refers to the extent people continue to use HL, assessed as the level and measures of engagement and participation in the HL programme, e.g., registered vs. attended and registered vs. completed.• Learn Journey: The structured part of the HL programme comprising one-page articles grouped into sections. Participants are required to work through them in a defined order (i.e., Section 2 only becomes available after the participant has completed Section 1, etc.) The majority of the Learn Journey is the same for all participants, but there is some variation depending on whether participants opt to receive information on smoking, driving and working. Definitions used to define the study population groups. 2.3. Ethics statement This study was reviewed and approved by the Yorkshire & The Humber – Leeds West Research Ethics Committee on 18 August 2020 (reference number: 20/YH/0250). The research team undertook secondary analysis of pseudonymised datasets and were not responsible for data collection or obtaining informed consent. 2.4. Data analysis 2.4.1. Uptake and retention of Healthy Living. Descriptive analysis and regression modelling were used to analyse socio-demographic and health characteristics of participants in Healthy Living, compared with NDA controls who did not participate. These analyses aimed to provide insights into differences in the characteristics of people who participated at various stages and allowed us to understand whether there was variation in participation. The outcomes of interest were binary measures of programme participation and attendance (described below). Continuous variables were described as mean and standard deviation (SD) or, if non-normally distributed, as median and interquartile range (IQR). Categorical variables were described as frequencies and percentages. Baseline socio-demographic, clinical measures and treatments reported for each of five study groups were: age, sex, ethnicity (White, Black, Asian, Mixed, Other), smoking status (current smoker, ex-smoker, non-smoker, never smoker), index of multiple deprivation (IMD) quintiles (IMD Q1 denotes most deprived areas, IMD Q5 for least deprived areas), Healthy Living referral route, HbA1c, BMI, systolic and diastolic blood pressure, total cholesterol, serum creatinine, T2DM duration, comorbidities (ischemic heart disease (IHD), history of CVD admission, learning disability (LD), and severe mental illness (SMI)), and baseline prescriptions of antihypertensive drugs, insulin, non-insulin diabetes drugs, and statins. Using multivariable logistic regression models, we estimated adjusted odds ratios (OR) and 95% confidence intervals (95% CI) to examine what factors are related to participation in the programme at every stage. We evaluated the association between the aforementioned baseline measures and various measures of participation by fitting regression models for the following paired groups: not registered (Group 1) vs. Healthy Living account activators (Group 3); not registered (Group 1) vs. Healthy Living attendees (Group 4); not registered (Group 1) vs. Healthy Living completers (Group 5); Group 3 vs. Group 4; and Group 3 vs. Group 5. We also evaluated the association between baseline measures and two measures of engagement: firstly, the total time spent on the programme website (dependent variable modelled as ≤ median time vs. > median); and secondly, the number of sessions visited on the website throughout the programme (dependent variable modelled as 1 session vs. > 1 sessions). A session was defined as a string of continuous activity on the website, ending when the user was inactive for over 10 minutes. Sub-group analyses were as described above but categorized by the timing of Healthy Living account activation as participants activating an account up to 31/08/2021 are part of the development and testing phase (Phase 1), while participants activating an account from 01/09/2021 are part of the finalised version (Phase 2). 2.4.2. Effectiveness of Healthy Living. Using a matched cohort study design, these analyses were based on Healthy Living cases with T2DM registered for Healthy Living up to 31st March 2022, matched to NDA controls. The 1-year outcomes were HbA1c (primary outcome), BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), and two binary outcomes: eight diabetes care processes, and new insulin use. Care processes were utilised as a marker for the quality of a patient’s diabetes care, as general practices offer people with T2DM a standardised set of annual care processes to help in early identification of diabetes complications [30]. In the UK, the eight care processes include HbA1c, blood pressure, BMI, foot risk surveillance, serum cholesterol, serum creatinine, smoking status, and urine albumin/creatinine ratio. Descriptive statistics for all baseline measures of the matched cohorts were described as above. We employed a sequential 1:5 case-control propensity score matching, to adjust for pre-treatment observable differences between a group of cases (Healthy Living registrants) and a group of untreated participants (NDA controls not registered with Healthy Living programme). Cases and controls were matched on age, sex, baseline HbA1c, BMI, SBP, total cholesterol, ethnicity, and IMD quintile using the -psmatch2- Stata command with a caliper size of 0.002. Multiple imputation using the mi suite of commands in Stata was used to impute missing values of baseline variables and outcomes (10 imputations). We included all covariates, including outcomes (effectiveness analyses), regardless of missingness level [31]. Matching was based on data imputed in the first imputation (m = 1) out of 10 imputations. Multivariable linear and logistic regression models were fitted using the -mi estimate- Stata command with robust standard errors to account for clustering by case-control matching identifiers. Unless otherwise stated, all multivariable models were adjusted for the binary case-control status variable, age, sex (vs. reference category: male), ethnicity (vs. reference: White), IMD quintiles (vs. reference: most deprived), smoking status (vs. reference: never smoked), BMI, and T2DM duration; baseline IHD (vs. reference: unknown), history of CVD admission (vs. reference: unknown), LD (vs. reference: unknown), and SMI (vs. reference: diagnosis not provided); baseline antihypertensive drugs, insulin, non-insulin diabetes drugs, and statins. To proxy for diabetes severity, the insulin use outcome was defined as new insulin use in participants who were not prescribed insulin at baseline. Several sensitivity analyses were conducted to test the robustness of the main analysis: i) excluded variables that are imbalanced by 5% and 10% between matched cases and controls; ii) regression models limited to participants with complete data, i.e., as a complete case analysis (CCA); iii) matched cohorts and analyses based on different imputations (m = 5 and m = 9). Sub-group analyses were also conducted and included: i) explore sub-groups that potentially benefit the most or the least from the intervention, by modelling the relationship between the intervention and a population characteristic (age, sex, ethnicity, IMD) as an interaction term in the regression models; ii) analyses limited to Healthy Living attendees and completers; iii) explore the association between outcomes and key general practice-level characteristics: list size, proportion of people with T2DM, deprivation, and urban/rural classification; iv) explore effectiveness of Healthy Living by the timing of Healthy Living account activation (Phases 1 and 2). In accordance with mandatory data provider Statistical Disclosure Control (SDC) rules (such as, rounding and small number suppression), individual categories may not sum to the total, and percentages may not sum to 100% in the reported results. All analyses were performed using Stata Statistical Software, Release 18 [32]. 3. Results 3.1. Uptake and retention of Healthy Living A total of N = 21,820 people activated a Healthy Living account between May 2020 and March 2022, N = 8,375 (38%) attended, while N = 990 (5%) people completed the Healthy Living programme (Fig 1, S1 Table). Flow diagram of the included cohort. Assessing uptake (Fig 2), people who activated an account, compared with NDA controls, were more likely to be female (OR: 1.91; 95% CI: 1.85–1.96), or from least deprived areas (OR: 2.09; 95% CI: 2.00–2.19) compared with most deprived areas, or to be prescribed non-insulin diabetes medication (OR: 2.17; 95% CI: 2.10–2.25), but less likely to be Asian (OR: 0.35; 95% CI: 0.33–0.37) or Black (OR: 0.56; 95% CI: 0.52–0.60) compared with White people, or current smokers (OR: 0.49; 95% CI: 0.47–0.52) compared with never smokers (Fig 2). Some participants met more >1 exclusion criterion; therefore, numbers may not sum exactly. Baseline predictors of Healthy Living (HL) uptake (activators) in comparison to NDA controls (odds ratios OR, 95%CI). BMI: body mass index; CVD: cardiovascular disease; DBP: diastolic blood pressure; HbA1c: glycated haemoglobin; HL: Healthy Living; H/o: history of; IHD: ischaemic heart disease; IMD Q: index of multiple deprivation quintile; LD: learning disability; NDA: National Diabetes audit; OR: odds ratio; Rx: prescription; SBP: systolic blood pressure; T2DM: type 2 diabetes. Models were adjusted for: age, sex (reference category: male), ethnicity (reference category: White), IMD quintiles (reference category: most deprived), smoking status (reference category: never smoked), BMI, and T2DM duration; baseline ischemic heart disease (reference category: unknown), history of cardiovascular disease admission (reference category: unknown), learning disability (reference category: unknown), and severe mental illness (reference category: diagnosis not provided); baseline prescriptions of antihypertensives, insulin, non-insulin diabetes medications, and statins. Assessing retention, people who attended Healthy Living, compared with those who activated an account but did not attend, were on average more likely to be female (OR: 1.35; 95% CI: 1.27–1.44) (S1 Fig), from least deprived areas compared with most deprived areas (OR: 1.11; 95% CI: 1.02–1.22), but less likely to be of Asian (OR: 0.53; 95% CI: 0.48–0.60) or Black ethnicity (OR: 0.57; 95% CI: 0.49–0.67) compared with White ethnicity, or to be prescribed non-insulin diabetes medication (OR: 0.79; 95% CI: 0.73–0.85) (S1 Fig). Similar results were also found when comparing Healthy Living completers with those who activated an account but did not complete, despite a relatively small number of completers. Among account activators with available engagement data, the median time spent on Healthy Living website was 6.9 mins (IQR 0.4–26.3). We compared longer attendees, who attended for more than the median time (N = 10,710), and shorter attendees, who attended for the median or less (N = 10,730). Longer attendees were, on average less likely to be male or to be of Asian or Black ethnicity, less likely to be prescribed insulin or non-insulin diabetes medication or statins, and their time since T2DM diagnosis was lower than shorter attendees (S2 Table). People who attended multiple sessions, were on average older, less likely to be male or to be of Asian ethnicity, to be from the most deprived areas, prescribed non-insulin diabetes medication or statins, and their time since T2DM diagnosis was shorter when compared with those who attended one session (S3 Table). 3.2. Effectiveness of Healthy Living Overall, N = 4,940 Healthy Living account activators were matched to N = 24,685 controls; N = 1,660 attendees matched to N = 8,290 controls; and N = 245 completers matched to N = 1,215 controls. Matching resulted in balanced baseline characteristics for most variables, except some, e.g., smoking status, history of CVD, and completion of care processes (S4 and S5 Tables). After adjusting for available baseline characteristics and health measures, participants who activated a Healthy Living account had lower HbA1c at 1 year (primary outcome), on average, than those in a matched NDA control group, by −1.3 mmol/mol (95% CI: −1.7, −0.8) or −0.1% (95% CI: −0.2, −0.1) in Diabetes Control and Complications Trial (DCCT) units (S6 Table, Fig 3). After similar adjustments, participants who activated a Healthy Living account had lower values for secondary outcomes, BMI (−0.2 kg/m2; 95% CI: −0.3, −0.1), systolic blood pressure (−1.2 mmHg; 95% CI: −1.6, −0.7), and diastolic blood pressure (−0.6 mmHg; 95% CI: −0.9, −0.3) at 1 year, compared with control, and higher odds of completing diabetes eight care processes (OR: 1.6; 95% CI: 1.5, 1.8) compared with controls (Table 2). 10.1371/journal.pone.0348266.t002Table 2Multivariable-adjusted difference (95% CI) in 1-year outcomes in Healthy Living (HL) account activators compared with NDA controls (N = 29,625).Differences (95% CI) in outcomes Linear regression models (Beta coefficient, 95% CI) HbA1c (mmol/mol)−1.3 (−1.7; −0.8)HbA1c (%)−0.1 (−0.2; −0.1)Body mass index (BMI) (kg/m2)−0.2 (−0.3; −0.1)Systolic blood pressure (SBP) (mmHg)−1.2 (−1.6; −0.7)Diastolic blood pressure (DBP) (mmHg)−0.6 (−0.9; −0.3) Logistic regression models (OR, 95% CI) Insulin use1.0 (0.8; 1.2)Completion of eight care processes1.6 (1.5; 1.8)HbA1c: glycated haemoglobin; HL: Healthy Living; NDA: National Diabetes audit; OR: odds ratio.Models were adjusted for: age, sex (reference category: male), ethnicity (reference category: White), IMD quintiles (reference category: most deprived), smoking status (reference category: never smoked), BMI, and T2DM duration; baseline ischemic heart disease (reference category: unknown), history of cardiovascular disease admission (reference category: unknown), learning disability (reference category: unknown), and severe mental illness (reference category: diagnosis not provided); baseline prescriptions of antihypertensives, insulin, non-insulin antidiabetic medications, and statins. Multivariable-adjusted difference (95% CI) in 1-year outcomes in Healthy Living (HL) account activators compared with NDA controls (N = 29,625). HbA1c: glycated haemoglobin; HL: Healthy Living; NDA: National Diabetes audit; OR: odds ratio. Models were adjusted for: age, sex (reference category: male), ethnicity (reference category: White), IMD quintiles (reference category: most deprived), smoking status (reference category: never smoked), BMI, and T2DM duration; baseline ischemic heart disease (reference category: unknown), history of cardiovascular disease admission (reference category: unknown), learning disability (reference category: unknown), and severe mental illness (reference category: diagnosis not provided); baseline prescriptions of antihypertensives, insulin, non-insulin antidiabetic medications, and statins. Covariate-adjusted 1-year HbA1c beta coefficients (95% CI) in Healthy Living (HL) account activators compared with NDA controls. BMI: body mass index; CVD: cardiovascular disease; DBP: diastolic blood pressure; HbA1c: glycated haemoglobin; HL: Healthy Living; H/o: history of; IHD: ischaemic heart disease; IMD Q: index of multiple deprivation quintile; LD: learning disability; NDA: National Diabetes audit; OR: odds ratio; Rx: prescription; SBP: systolic blood pressure; T2DM: type 2 diabetes. Models were adjusted for: age, sex (reference category: male), ethnicity (reference category: White), IMD quintiles (reference category: most deprived), smoking status (reference category: never smoked), BMI, and T2DM duration; baseline ischemic heart disease (reference category: unknown), history of cardiovascular disease admission (reference category: unknown), learning disability (reference category: unknown), and severe mental illness (reference category: diagnosis not provided); baseline prescriptions of antihypertensives, insulin, non-insulin diabetes medications, and statins. The results of all sensitivity analyses were consistent with the main findings (S7-S9 Tables), except that effect was not statistically significant in the CCA based on a small cohort. In the first sub-group analysis, all interaction terms were not statistically significant, suggesting no evidence of a difference in effect size between any sub-groups, apart from the case-sex interaction that was statistically significant, indicating that the effect on 1-year HbA1c change in men was greater than among women. In the second sub-group analysis, Healthy Living attendees had lower 1-year HbA1c levels than matched NDA controls by −2.3 mmol/mol (95% CI: −3.0, −1.6) and completers by −4.0 mmol/mol (95% CI: −6.1, −1.9) (S10 Table). We found no evidence of an association between the 1-year HbA1c and practice-level characteristics (third sub-group analysis). The effect of activating a Healthy Living account, compared with NDA matched controls was similar for all outcomes, regardless of whether the account was activated during the development/testing or finalised phases (fourth sub-group analysis, S11 Table). 4. Discussion 4.1. Summary of the findings In this study, we included a large cohort of over 3 million people with T2DM in England, of which a small proportion (0.7%) registered with Healthy Living programme or activated an account. The main predictors of activating a Healthy Living account (uptake) included being female sex, from least deprived areas, and White ethnicity. We observed that, compared with controls, people who activated their Healthy Living account had statistically significant reductions in health outcomes, except new insulin use, including lower 1-year levels of HbA1c (−1.3 mmol/mol); BMI (−0.2 kg/m2), systolic BP (−1.2 mmHg), and diastolic BP (−0.6 mmHg); and had a 1.6-fold higher odds of completing eight care processes. These benefits on outcomes were greater in those who attended or completed the programme i.e., participants with higher engagement. The sensitivity and sub-group analyses showed overall similar results to those from the main analysis, however, with caveats of limited power due to the smaller cohorts included in some of these analyses. 4.2. Findings in light of current literature Unlike in clinical trials that are mainly based on pre-selected population, we present a real-world population-based assessment of an online free universally accessible DSMES programme, while assessing a range of clinical outcomes. In comparison with HeLP-Diabetes [25], participants who activated an account with Healthy Living observed a smaller reduction in HbA1c level at 1 year (HL mean difference: −1.3 mmol/mol; 95% CI: -1.8, −0.9 vs. HeLP-Diabetes −2.6; 95%CI: −4.8, −0.5) (S12 Table). Healthy Living also showed a smaller effect on SBP at 1 year (mean difference: Healthy Living −1.2 mmHg vs. HeLP-Diabetes −3.8 mmHg). Healthy Living was associated with reduced BMI (mean difference: −0.2 kg/m2), reduced diastolic blood pressure (mean difference: −0.9 mmHg), and greater completion of the eight care processes (OR: 1.6), unlike in the HeLP-Diabetes trial which found no evidence of a difference on these outcomes. Importantly, because of the larger sample size in our analyses than the HeLP-Diabetes trial, there was less uncertainty around our estimates (S12 Table). In comparison with other DSMES interventions, a meta-analysis of digital DSMES interventions in adults with T2DM from eight randomised trials reported a mean difference of −0.6% (−1.0, −0.2) in 1-year HbA1c [20]. These eight trials included a total of 657 participants with T2DM in the intervention arm and 587 participants in the control arm, while assessing different digital interventions, such as web-based, mobile text and/or video messages. Additionally, they reported that interventions that offered multiple digital routes (e.g., mobile, social media) and/or multiple digital tools (e.g., text messages) showed better impact on glycaemic control than other tools. The smaller effects in Healthy Living of −0.1% (−0.2, −0.1) compared to those trials’ digital DSMES interventions (−0.6%) maybe driven by greater clinical input, personalisation and resource use, real-time phone/text support, and/or reminders for self-care activities in those interventions. An HbA1c reduction of 3–5 mmol/mol [33,34] is considered to be clinically significant for reducing the risk of diabetes-related complications at the individual patient level [33]. Although the improvement in HbA1c in our study (1.3 mmol/mol) is smaller, such modest effects can be common in real-world evaluations where patient characteristics, varied engagement and attitudes towards glucose control, and routine practice conditions may affect the magnitude of observed change compared to controlled trials. Nonetheless, this small average reduction can potentially provide modest benefits at population level for reducing the risk of developing long-term diabetes-related microvascular and macrovascular complications. Overall, the observed variation in Healthy Living uptake aligns with evidence from other chronic condition self-management programmes [23]. In the UK, retention in the myDESMOND digital DSMES was lower in people aged <50 years, while engagement was lower in people aged <50 years, males, and non-White users [35]. myDESMOND is a digital DSMES programme for ongoing and newly diagnosed diabetes with 21,285 users. DSMES services need to address the challenge of improving access among those groups of society most in need of such programmes, for example people with lower socioeconomic status [23] and from ethnic minority communities. 4.3. Strengths and limitations Our study has several strengths. First, this is a real-world evaluation of a freely available digital intervention supporting self-management for people with T2DM. Second, we used a large dataset combining the Healthy Living datasets and the latest NDA, which contains real-world data for more than 3 million people with T2DM in England. Third, using a matched control group, we evaluated intervention-related changes in clinically relevant risk factors and outcomes that predict risk for developing serious long-term diabetes-related complications. Fourth, methodologically robust data analyses were employed, including multiple imputation and sequential propensity score matching to deal with confounding and to ensure robustness and the clinical relevance of the findings. Fifth, several sub-group and sensitivity analyses were performed and demonstrated the robustness of the findings reported in the main analysis, despite some caveats outlined below. Nevertheless, the study had a few limitations that may necessitate cautious interpretation of some of the reported findings. First, our follow-up period was only 1 year; longer follow-up would be desirable to assess if treatment-related differences are maintained. Second, the NDA data coverage was until March 2023 which was six months shorter than the Healthy Living registrations up to September 2023, and so to ensure participants had up to 1 year of follow-up NDA data, we restricted the Healthy Living cohort in the effectiveness analyses to participants registered up to March 2022, which reduced the sample size to only 25% of the total Healthy Living cohort. Third, the COVID-19 pandemic caused delays to general practice referral routes to Healthy Living [36], leading to lower than expected uptake of the service, and hence the diversity of registrants, in the first months of rollout of the programme. Fourth, some sensitivity and sub-group analyses were limited in power. Fifth, while we addressed confounding by controlling for measured characteristics, there may be unmeasured variations between patients which account for the differences in outcomes between groups. Sixth, no data was available to assess the impact of medication intensification on the observed effectiveness findings. Finally, the datasets lacked information on diabetes-related complications which are important outcomes in people with diabetes. 4.4. Potential clinical and research implications Our findings showed modest improvements in HbA1c levels and other clinical outcomes at 1-year of Healthy Living account activation. At a population-level, the potential clinical implications are anticipated to be modest reductions in incident diabetes-related microvascular and macrovascular complications. Additionally, the intervention has potential to reduce clinical workload in primary care settings by providing patients with valuable information about diabetes. Our findings may help inform the development of new interventions to foster uptake and engagement, addressing any inequalities between population groups in DSMES programmes. Future research may use larger cohorts with recent Healthy Living data that are better aligned with the NDA, and possibly linked to hospitalisation data to assess further diabetes-related outcomes over a longer period. Further research may also identify predictors of variation in access to the intervention and similar DSMES programmes. 5. Conclusions People who activated a Healthy Living account experienced, on average, modest but statistically significant health benefits compared with non-participants, and the benefits were greater in those with higher adherence. At population level these benefits would be expected to translate into modest reductions in risks for developing incident diabetes-related complications. Supporting information Baseline characteristics of the study groups. (PDF) Logistic regression model for ‘Attendance’ using total time spent on the website (total duration in minutes) measure as binary outcome of total time being ≤ median of 6.85 minutes (reference group) vs. > median time (N = 21,440 HL participants with usage data). (PDF) Logistic regression model for ‘Attendance’ using visits frequency measure as binary outcome of session number = 1 session (reference group) vs. > 1 session. Defined as the total number of sessions on the website visited per participant throughout the programme (N = 21,445 HL participants with usage data). (PDF) Baseline characteristics of the 1:5 matched HL cases-controls cohort study Groups 1 and 3. (PDF) Baseline characteristics of the 1:5 matched HL cases-controls cohort- groups 1 & 4 and groups 1 and 5. (PDF) Linear regression model output for 1-year HbA1c (mmol/mol) – primary outcome (N = 29,625). (PDF) Multivariable-adjusted difference (95% CI) in 1-year outcomes in HL account activators (cases) compared with matched NDA controls, excluding covariates with more than 5 or 10 percent imbalances between cases and controls. (N = 29,625). (PDF) Multivariable-adjusted difference (95% CI) in 1-year HbA1c model limited to participants with complete non-missing data Using matched HL activators and NDA controls cohort) (complete case analysis, CCA). (PDF) Multivariable-adjusted difference (95% CI) in 1-year outcomes based on different imputations (Using matched HL activators and NDA controls cohort). (PDF) Multivariable-adjusted difference (95% CI) in 1-year outcomes in HL account activators, HL attendees and HL completers compared with NDA controls. (PDF) Multivariable-adjusted difference (95% CI) in 1-year outcomes in matched HL cases and NDA controls across different HL development phases. (PDF) Comparison of results of selected outcomes with results from the HeLP-Diabetes trial. (PDF) Baseline predictors of HL retention (attendees) in comparison to HL activators (odds ratios, 95%CI). (PDF) Transfer Alert This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present. 7 Jul 2025 19 Jan 2026 -->PONE-D-25-33501-->-->Examining the uptake, retention, and effectiveness of a national online type 2 diabetes self-management intervention in England (Healthy Living): a retrospective cohort study-->-->PLOS One Dear Dr. Zghebi, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== ACADEMIC EDITOR: While the manuscript exhibits intriguing potential, it requires substantial revisions and further refinement. Although the inherent interest in the subject matter is acknowledged, the reviewers have raised crucial concerns that must be properly addressed. ============================== Please submit your revised manuscript by Mar 05 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Marcelo Arruda Nakazone, M.D., Ph.D. Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following in the Competing Interests section: “MKR reports receiving consulting fees from Eli Lilly and modest GSK stock ownership both unrelated to this work. He has also led research at the University of Manchester with Innovate UK and NIHR funding to independently evaluate My Diabetes My Way, a digital intervention supporting the management of diabetes. Other authors declare no conflicts of interest.” We note that one or more of the authors are employed by a commercial company: GSK 1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form. Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement. 2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. 3. Thank you for stating the following financial disclosure: “This paper reports independent research funded by the National Institute for Health and Care Research (Policy Research Programme, HED-LINE, NIHR200933).” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 4. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. “Yes: 2 text-only abstracts briefly outlining the results were submitted to academic conferences” Please clarify whether this [conference proceeding or publication] was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript. 5. Please note that your Data Availability Statement is currently missing the DOI/accession number of each dataset OR a direct link to access each database. If your manuscript is accepted for publication, you will be asked to provide these details on a very short timeline. We therefore suggest that you provide this information now, though we will not hold up the peer review process if you are unable. 6. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: No ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Abstract (results): Can the authors indicate which values are crude ORs and the 95%CIs through the results for consistency? Main manuscript Line 143: Delete fullstop (.) Line 186: Do you mean values or variables? If variables, can you explain this was done beyond the stated STATA command used? Line 221: For consistency, can all 95%CIs be presented in this style? Line 225: From which table comes this results? Line 232: From which table or figure comes this results, i.e. line 232-240? Line 233: Please add the IQR. All the tables need to be checked for: 1. Most percentages are not up to 100% or more than 100%. Please check the whole table 2. Some figures that needed percentages were not added (e.g. Table S1, Ethnicity - Mixed, and Other) These apply to most percentages. Reviewer #2: In this paper, the authors reported effectiveness of online intervention in England (Healthy Living; HL), as compared to the matched-controls (NDA). The online intervention resulted in modest improvements in several metabolic parameters after 1 year. The results are almost clearly presented, and the analyses seemed to be well performed. The reviewer’s comments are as follows. 1. The contents of Healthy Living are not clearly described. Some supplementary information would be helpful. 2. Please add the description regarding ethical approval by the institution, in the main text. 3. The participants in HL program and the matched-controls (NDA) are essentially different. The participants in HL program were younger with shorter duration of diabetes and with lower past history of ischemic heart disease (Table S1). The participants in HL program might have more positive attitude to improve their glucose control. Also, there are no consideration on treatment intensification during the period. Therefore, much more caveats should be added on the improvements in metabolic parameters. 4. The improvement in HbA1c levels may be smaller than that anticipated. Some more discussion should be made regarding this observation. 5. Results, Figure 1. Were the participants who attended the program (n=8375) included those with HL account (n=21820)? If so, revise Figure 1 to avoid confusion. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: Yes: Clement Tetteh Narh Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 12 Feb 2026 Dear Editor, Re. PONE-D-25-33501 - Examining the uptake, retention, and effectiveness of a national online type 2 diabetes self-management intervention in England (Healthy Living): a retrospective cohort study Thank you for the opportunity to submit a revision of our manuscript. Below, we provide a point-by-point response to the received comments. To facilitate the review process, all changes are highlighted in the revised manuscript and numbered by the Reviewer and comment numbers. For example, “Response to Reviewer 1, comment #1”. We hope to have satisfactorily responded to the comments, which have strengthened our manuscript. Looking forward to receiving your decision. Yours sincerely, Corresponding Author, on behalf of the authors Academic Editor Journal Requirements: When submitting your revision, we need you to address these additional requirements. I. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf [journals.plos.org] and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf [track.editorialmanager.com] Authors response We reviewed the manuscript and confirm that it meets the PLOS ONE’s style requirements. II. Thank you for stating the following in the Competing Interests section: “MKR reports receiving consulting fees from Eli Lilly and modest GSK stock ownership both unrelated to this work. He has also led research at the University of Manchester with Innovate UK and NIHR funding to independently evaluate My Diabetes My Way, a digital intervention supporting the management of diabetes. Other authors declare no conflicts of interest.” We note that one or more of the authors are employed by a commercial company: GSK 1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form. Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement. Authors response We confirm that the commercial affiliation did not play any role in this study. The Funding Statement has been revised to declare this commercial affiliation and the proposed statement has been also included. The amended Funding Statement now reads as follows in the manuscript: “This paper reports independent research funded by the National Institute for Health and Care Research (Policy Research Programme, HED-LINE, NIHR200933). The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health and Care Research or the Department of Health and Social Care. The funder did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Eli Lilly provided support in the form of consulting fees for MKR, unrelated to this work, and did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of MKR is articulated in the ‘author contributions’ section. EK is part-funded by the NIHR HeatlhTech Research Centre in Emergency and Acute Care (NIHR205301) and the Manchester British Heart Foundation (BHF) Centre for Research Excellence (RE/24/130017).” 2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests [journals.plos.org]) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. Authors response Both updated Funding Statement and Competing Interests Statement has been included in the cover letter. The proposed statement has been added to the Competing Interests Statement, and it now reads as: “MKR reports receiving consulting fees from Eli Lilly and modest GSK stock ownership both unrelated to this work. He has also led research at the University of Manchester with Innovate UK and NIHR funding to independently evaluate My Diabetes My Way, a digital intervention supporting the management of diabetes. This does not alter our adherence to PLOS ONE policies on sharing data. Other authors declare no conflicts of interest.” 3. Thank you for stating the following financial disclosure: “This paper reports independent research funded by the National Institute for Health and Care Research (Policy Research Programme, HED-LINE, NIHR200933).” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. Authors response The proposed statement has been added to the Funding Statement, added to the cover letter and it now reads as: “This paper reports independent research funded by the National Institute for Health and Care Research (Policy Research Programme, HED-LINE, NIHR200933). The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health and Care Research or the Department of Health and Social Care. The funder did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Eli Lilly provided support in the form of consulting fees for MKR, unrelated to this work, and did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of MKR is articulated in the ‘author contributions’ section. EK is part-funded by the NIHR HeatlhTech Research Centre in Emergency and Acute Care (NIHR205301) and the Manchester British Heart Foundation (BHF) Centre for Research Excellence (RE/24/130017).” 4. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. “Yes: 2 text-only abstracts briefly outlining the results were submitted to academic conferences” Please clarify whether this [conference proceeding or publication] was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript. Authors response Thank you for this comment. We have explained how this work does not constitute dual publication in the cover letter. Both abstracts were peer-reviewed by internal conference committees, but only one abstract was published in Diabetic Medicine supplementary issue (Diabetes UK Conference, 2025). Each abstract contains a succinct text-only summary, without detailed methodology, full results, figures/tables. The current manuscript submitted to PLOS ONE includes substantial new content, including full methods, analyses, results, and conclusions, which have never been published elsewhere. No copyright was transferred as part of the conference abstract publication. For transparency, we have fully disclosed the submission of abstracts, and we confirm that this manuscript submission does not constitute duplicate or prior publication under PLOS ONE’s policies or ICMJE Recommendations. 5. Please note that your Data Availability Statement is currently missing the DOI/accession number of each dataset OR a direct link to access each database. If your manuscript is accepted for publication, you will be asked to provide these details on a very short timeline. We therefore suggest that you provide this information now, though we will not hold up the peer review process if you are unable. Authors response The data underlying the results presented in the study are only available through the data provider ‘NHS England’ and authors were not provided with and DOI/accession number. All interested researchers can request to access the data through NHS England directly and authors are not permitted to share the data publicly (even as minimal underlying dataset) or make it available as per the data use agreement with NHS England. The authors did not have any special access privileges to this data. 6. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. Authors response The following ethics statement is now included in the Methods section of the manuscript as follows: “This study was reviewed and approved by the Yorkshire & The Humber - Leeds West Research Ethics Committee on 18 August 2020 (reference number: 20/YH/0250). The research team undertook secondary analysis of pseudonymised datasets and were not responsible for data collection or obtaining informed consent.” 7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information [journals.plos.org]. Authors response Captions for the Supporting Information files are now added at the end of the manuscript, and in-text citations have also been reviewed and updated. 8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Authors response The reviewers' comments did not recommend including additional references; hence no new citations were added to the manuscript. Reviewer #1 Abstract (results): 1) Can the authors indicate which values are crude ORs and the 95%CIs through the results for consistency? Authors response Thank you for this comment. All reported ORs are estimated using multivariable logistic regression models i.e. adjusted ORs. We did not feel univariable associations would add any value to the paper, and any such estimates were not directly relevant to our research question. We have now corrected this in the abstract to indicate that all reported ORS are adjusted ORs. Changes to the paper • Abstract: Removed any mention of ‘aOR’ from the abstract and all are now reported as 'OR' for consistency. • Methods section (Line 170): the relevant text now reads as “Using multivariable logistic regression models, we estimated adjusted odds ratios (OR) and 95% confidence intervals (95% CI)…” Main manuscript: 2) Line 143: Delete fullstop (.) Authors response The full stop has been deleted. Changes to the paper The text now reads as: "2.4.1. Uptake and retention of Healthy Living" 3) Line 186: Do you mean values or variables? If variables, can you explain this was done beyond the stated STATA command used? Authors response We thank the reviewer for this comment. We meant values of baseline variables and have revised the text for clarity. Changes to the paper The text now reads as (Line 195): "Multiple imputation using the mi suite of commands in Stata was used to impute missing values of baseline variables and outcomes (10 imputations)." 4) Line 221: For consistency, can all 95%CIs be presented in this style? Authors response All 95% CIs have been revised and presented as per the suggested style throughout the paper. 5) Line 225: From which table comes this results? Authors response and Changes to the paper We would clarify to the reviewer that the reported results of the retention analysis are presented in Figure S1 which is now cited earlier in the text for clarity (Line 253). 6) Line 232: From which table or figure comes this results, i.e. line 232-240? Authors response Thank you for this comment and we apologise for the omission. Changes to the paper In response to this comment, the full tables have now been added to the supplementary file as Tables S2 and S3 and cited in the main manuscript as follows (Line 264-267): “We compared longer attendees, who attended for more than the median time (N=10,710), and shorter attendees, who attended for the median or less (N=10,730). Longer attendees were, on average less likely to be male or to be of Asian or Black ethnicity, less likely to be prescribed insulin or non-insulin diabetes medication or statins, and their time since T2DM diagnosis was lower than shorter attendees (S2 Table). People who attended multiple sessions, were on average older, less likely to be male or to be of Asian ethnicity, to be from the most deprived areas, prescribed non-insulin diabetes medication or statins, and their time since T2DM diagnosis was shorter when compared with those who attended one session (S3 Table).” 7) Line 233: Please add the IQR. Authors response and Changes to the paper Thank you for this comment. The IQR has now been added to the manuscript and reads as (Line 260): “….the median time spent on Healthy Living website was 6.9 mins (IQR 0.4 - 26.3).” All the tables need to be checked for: 8) Most percentages are not up to 100% or more than 100%. Please check the whole table Authors response We would like to highlight that we have been directed to apply the data provider's Statistical Disclosure Control rules to all reported figures which involved: ‘Small Number Suppression’ and ‘Rounding’ figures to the nearest five to prevent identification. As a result, it is standard for totals and percentages to not sum exactly, and we confirm that it does not indicate an error in the analysis or reporting. Changes to the paper We have added the following text in the Methods section and as a footnote to all tables to indicate the reason of any apparent total/percentage discrepancies, and it reads as follows: “In accordance with mandatory data provider Statistical Disclosure Control (SDC) rules (such as, rounding and small number suppression), individual categories may not sum to the total, and percentages may not sum to 100%.” 9) Some figures t Submitted filename: Response to Reviewers.pdf 14 Apr 2026 Examining the uptake, retention, and effectiveness of a national online type 2 diabetes self-management intervention in England (Healthy Living): a retrospective cohort study PONE-D-25-33501R1 Dear Dr. Zghebi, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Marcelo Arruda Nakazone, M.D., Ph.D. Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #2: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #2: Thank you for your rigorous revision. This reviewer thinks that the paper is now found to be acceptable. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #2: No ********** PONE-D-25-33501R1 PLOS One Dear Dr. Zghebi, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Professor Marcelo Arruda Nakazone Academic Editor PLOS One